PHASE 2 STUDY OF ALDOXORUBICIN VERSUS TOPETECAN FOR RELAPSED/REFRACTORY SMALL CELL LUNG CANCER

被引：0
|
作者：
Wieland, S. [1 ]
Mita, A. [2 ]
Piantadosi, S. [2 ]
Natale, R. [2 ]
Levitt, D. [3 ]
机构：
[1] CytRx Corp, Clin Operat, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] CytRx Corp, Clin Dev, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu355.16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1478TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Venepalli, N. K.
    Hutchison, A. S.
    Carbone, D. P.
    Johnson, D. H.
    Keedy, V. L.
    Pao, W.
    Sandler, A.
    Horn, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Lovly, Christine Marie
    Li, Chung-I
    Hutchison, Anne Smith
    Carbone, David Paul
    Johnson, David H.
    Keedy, Vicki Leigh
    Pao, William
    Sandler, Alan
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer
    Schuette, Wolfgang
    Nagel, Sylke
    Juergens, Stefan
    Bork, Ines
    Wollschlaeger, Bettina
    Schaedlich, Steffen
    Blankenburg, Thomas
    CLINICAL LUNG CANCER, 2005, 7 (02) : 133 - 137
  • [24] Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
    Francesco Gelsomino
    Marcello Tiseo
    Fausto Barbieri
    Ferdinando Riccardi
    Luigi Cavanna
    Antonio Frassoldati
    Angelo Delmonte
    Lucia Longo
    Claudio Dazzi
    Saverio Cinieri
    Ida Colantonio
    Francesca Sperandi
    Giuseppe Lamberti
    Stefano Brocchi
    Lorenzo Tofani
    Luca Boni
    Andrea Ardizzoni
    British Journal of Cancer, 2021, 125 : 306 - 306
  • [25] EFFICACY OF AMRUBICIN IN PATIENTS WITH REFRACTORY RELAPSED SMALL CELL LUNG CANCER
    Wakuda, Kazushige
    Kenmotsu, Hirotsugu
    Oyakawa, Takuya
    Hisamatsu, Yasushi
    Kimura, Madoka
    Tokito, Takaaki
    Imai, Hisao
    Akamatsu, Hiroaki
    Ono, Akira
    Shukuya, Takehito
    Taira, Tetsuhiko
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S493 - S494
  • [26] Three Weekly Irinotecan for Refractory/Relapsed Small Cell Lung Cancer
    Nutalapati, S.
    Yan, D.
    Morgan, R.
    Chauhan, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1188 - S1188
  • [27] Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients
    Jacot, William
    Pujol, Jean-Louis
    Chakra, Mohammad
    Molinier, Olivier
    Bozonnat, Marie-Cecile
    Gervais, Radj
    Quantin, Xavier
    LUNG CANCER, 2012, 75 (02) : 213 - 216
  • [28] A Phase II Study of Vobramitamab Duocarmazine in Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
    Gupta, B.
    Zaemes, J. P.
    Yeung, V.
    Reuss, J.
    Aggarwal, V.
    Thompson, J.
    Swanson, N.
    Perez, D. de Miguel
    Ahn, J.
    Chen, K.
    Veytsman, I.
    Gutierrez, M.
    Rolfo, C. D.
    Liu, S. V.
    Kim, C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S661 - S662
  • [29] Current updates in management of relapsed/refractory small cell lung cancer
    Abughanimeh, Omar
    Ernani, Vinicius
    Marr, Alissa
    Ganti, Apar Kishor
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2020, 6
  • [30] Phase II study of ADI-PEG 20 in patients with relapsed sensitive or refractory small cell lung cancer
    Tran, Sinhan
    Ready, Neal
    Krug, Lee M.
    Pietanza, Maria Catherine
    Jungbluth, Achim A.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Hoffman, Eric W.
    Peters, Ann-Marie
    Dukelow, Karen
    Bomalaski, John S.
    Wu, Bor-Wen
    Old, Lloyd J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345